Source: Annual Congress 2004 - Therapy in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. L. Shaporova, V. I. Trofimov, T. P. Ses, M. A. Petrova, O. A. Ivanova (St Petersburg, Russia). Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma. Eur Respir J 2004; 24: Suppl. 48, 890

Member's Comments

No comment yet.

Related content which might interest you: The immunological features of the severe steroid-resistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003 The genetic markers of steroid-resistance in the patients with steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004 The glucocorticoid nuclear action peculiarities in the steroid-resistant patients with severe bronchial asthma Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Use of budesonide suspension during the exacerbation of severe steroid-dependent bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Clinical profile of patients with adult-onset eosinophilic asthma Source: ERJ Open Res 2016: 00100-2015 Year: 2016 Risk of bronchiectasis in bronchial asthma: steroid-dependent versus non-steroid-dependent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 508s Year: 2005 Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Pathophysiology of non-eosinophilic severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Clinical features and their link with asthma exacerbations amongst aspirin-induced asthmatics Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Clinical features of metamizole intolerant patients with/without bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 422s Year: 2002 Pathophysiology of severe non-allergic asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019